Moderate to Severe Plaque PsO | TREMFYA® (guselkumab) HCP

COMPLETE SKIN CLEARANCE

In VOYAGE 1 and VOYAGE 2, the co-primary endpoints of PASI 90 and IGA 0/1 at 16 weeks were met. A majority of patients (53%) in VOYAGE 1 achieved IGA 0 at Week 241-3

VIEW PsO DETAILS

CONSISTENT EFFICACY AND DURABLE RESPONSE RATES

In VOYAGE 1, PASI 90 response rates were consistent between doses from Week 20−48. In the open-label extension, response rates were maintained from Week 52−2521,4*

VIEW PsO DETAILS

RAPID JOINT IMPROVEMENT PROVEN TO LAST AT 2 YEARS

ACR20 response at Week 24 after just 4 doses (primary endpoint) and an OLE active treatment NRI post hoc analysis from Weeks 24 to 1001,4,5‡§

VIEW PsA DETAILS

BEST-IN-CLASS ACCESS AMONG THE IL-23s & SUPERIOR ACCESS TO THE
IL-17s||¶#

Nationally, 9 out of 10 patients with PsO have preferred,** first-line access for TREMFYA®

VIEW PsO DETAILS

#The information provided does not imply comparable safety or efficacy between products and only represents access information. Indicated trademarks are the registered trademarks of their respective owners. Please refer to each product’s prescribing information for indication(s), recommended dosing, and administration.

*Patients who lose response or are unable to tolerate treatment are likely to discontinue treatment, which may increase the response rate in an as-observed analysis. The same patients may not have responded at each time point.

Year 2 represents Week 100.

After Week 24, patients and doctors knew that all patients were on TREMFYA® (open label with a blinded dosing interval), which may have affected the results. The same patients may not have responded at each time point.

§In DISCOVER 1 and DISCOVER 2, adult patients with active PsA demonstrated a greater clinical response, including ACR20 (primary endpoint), compared to placebo at Week 24.

||Source: Managed Markets Insight & Technology, LLC™, a trademark of MMIT, as of May 2022.

”Best-in-class” means the number of first-line covered lives is greater for TREMFYA® than for other products in the IL-23 inhibitor class [(Skyrizi® (risankizumab-rzaa), Ilumya® (tildrakizumab-asmn)].

**"Preferred" means TREMFYA® can be accessed first-line (ie, step therapy is not required) and its formulary status is better than or equivalent to other products in the class.

IGA=Investigator’s Global Assessment, IGA score of cleared (0) or minimal (1) using a 5-point scale of overall disease severity; PASI=Psoriasis Area and Severity Index.

IN ADULTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS UNCOVER TREMFYA®

Teaser: 

{"@context":"https://schema.org/","@type":"Drug","name":"Tremfya","alternateName":"gu...{"@type":"Organization","name":"Janssen Pharmaceuticals, Inc.","url":"http://www.janassen.com/us/","contactPoint":[{"@type":"ContactPoint","telephone":"+1-800-526-7736","contactType":"customer service"}]}]}